All Stories

  1. Exploring genetic and immune underpinnings of the sexual dimorphism in tumor response to immune checkpoints inhibitors: A narrative review

    Article • Current Research in Pharmacology and Drug Discovery, January 2023, Elsevier

    Dr Sebastiano Buti

  2. BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients

    Article • Tumori Journal, December 2022, SAGE Publications

    Dr Sebastiano Buti

  3. A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)

    Article • Tumori Journal, November 2022, SAGE Publications

    Dr Sebastiano Buti

  4. Takotsubo syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab plus axitinib

    Article • Immunotherapy, November 2022, Future Medicine

    Dr Sebastiano Buti

  5. First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin

    Article • Annals of Oncology, November 2022, Elsevier

    Dr Sebastiano Buti

  6. The Geriatric G8 Score Is Associated with Survival Outcomes in Older Patients with Advanced Prostate Cancer in the ADHERE Prospective Study of the Meet-URO Network

    Article • October 2022, MDPI AG

    Dr Sebastiano Buti

  7. What Is the Real Impact of Concomitant Antibiotics or Proton Pump Inhibitors on Efficacy of Atezolizumab-Based Regimens in Patients With NSCLC?

    Article • Journal of Thoracic Oncology, October 2022, Elsevier

    Dr Sebastiano Buti

  8. Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma

    Article • Biomedicines, September 2022, MDPI AG

    Dr Sebastiano Buti

  9. The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study

    Article • Journal of Translational Medicine, September 2022, Springer Science + Business Media

    Dr Sebastiano Buti

  10. The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis

    Article • Frontiers in Oncology, September 2022, Frontiers

    Dr Sebastiano Buti

  11. Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma

    Article • European Journal of Cancer, September 2022, Elsevier

    Dr Sebastiano Buti

  12. Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade

    Article • European Journal of Cancer, September 2022, Elsevier

    Dr Sebastiano Buti

  13. A novel immunotherapy prognostic score for patients with pretreated advanced urinary tract carcinoma from the subgroup analysis of the SAUL study. The urInary TrAct CArcinoma score (ITACA)

    Article • August 2022, Cold Spring Harbor Laboratory Press

    Dr Sebastiano Buti

  14. Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors

    Article • Frontiers in Oncology, August 2022, Frontiers

    Dr Sebastiano Buti

  15. Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies

    Article • Targeted Oncology, August 2022, Springer Science + Business Media

    Dr Sebastiano Buti

  16. Reassessing Human Adipose Tissue

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, June 2022, New England Journal of Medicine (NEJM/MMS)

    Dr Sebastiano Buti

  17. Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma

    Article • JAMA Oncology, June 2022, American Medical Association (AMA)

    Dr Sebastiano Buti

  18. Comparing the prognostic models to predict oncologic outcomes in patients with renal cell carcinoma: is AUC close enough to clinical practice?

    Article • Urologic Oncology Seminars and Original Investigations, May 2022, Elsevier

    Dr Sebastiano Buti

  19. Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study

    Article • Journal of Personalized Medicine, April 2022, MDPI AG

    Dr Sebastiano Buti

  20. Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study

    Article • Clinical Genitourinary Cancer, April 2022, Elsevier

    Dr Sebastiano Buti

  21. Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study

    Article • Cancer Medicine, March 2022, Wiley

    Dr Sebastiano Buti

  22. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study

    Article • European Urology, March 2022, Elsevier

    Dr Sebastiano Buti

  23. Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives

    Article • Cancers, February 2022, MDPI AG

    Dr Sebastiano Buti

  24. Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?

    Article • Anticancer Research, February 2022, International Institute of Anticancer Research

    Dr Sebastiano Buti

  25. Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis

    Article • Immunotherapy, February 2022, Future Medicine

    Dr Sebastiano Buti

  26. Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group)

    Article • Immunotherapy, February 2022, Future Medicine

    Dr Sebastiano Buti

  27. Renal cell carcinoma and viral infections: A dangerous relationship?

    Article • World Journal of Nephrology, January 2022, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Sebastiano Buti

  28. High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status

    Article • Journal of Hematology & Oncology, January 2022, Springer Science + Business Media

    Dr Sebastiano Buti

  29. Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib

    Article • Therapeutic Advances in Medical Oncology, January 2022, SAGE Publications

    Dr Sebastiano Buti

  30. Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer

    Article • JAMA Oncology, December 2021, American Medical Association (AMA)

    Dr Sebastiano Buti

  31. Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)

    Article • Expert Review of Anticancer Therapy, November 2021, Taylor & Francis

    Dr Sebastiano Buti

  32. Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14)

    Article • Frontiers in Oncology, November 2021, Frontiers

    Dr Sebastiano Buti

  33. First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series

    Article • World Journal of Clinical Oncology, November 2021, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Sebastiano Buti

  34. Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature

    Article • Cancers, October 2021, MDPI AG

    Dr Sebastiano Buti

  35. Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients?

    Article • Transplant International, October 2021, Frontiers

    Dr Sebastiano Buti

  36. Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib

    Article • Tumori Journal, September 2021, SAGE Publications

    Dr Sebastiano Buti

  37. Review on radiological evolution of COVID-19 pneumonia using computed tomography

    Article • World Journal of Radiology, September 2021, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Sebastiano Buti

  38. Response to letter entitled: Re: Predictive ability of a drug-based score in advanced non-small cell lung cancer patients receiving first-line immunotherapy

    Article • European Journal of Cancer, September 2021, Elsevier

    Dr Sebastiano Buti

  39. Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial

    Article • European Journal of Cancer, September 2021, Elsevier

    Dr Sebastiano Buti

  40. Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation

    Article • Medical Oncology, August 2021, Springer Science + Business Media

    Dr Sebastiano Buti

  41. Differential diagnosis of COVID-19 at the chest computed tomography scan: A review with special focus on cancer patients

    Article • World Journal of Radiology, August 2021, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Sebastiano Buti

  42. Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study

    Article • Targeted Oncology, August 2021, Springer Science + Business Media

    Dr Sebastiano Buti

  43. PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort

    Article • Journal of Translational Medicine, June 2021, Springer Science + Business Media

    Dr Sebastiano Buti

  44. Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b)

    Article • Frontiers in Oncology, June 2021, Frontiers

    Dr Sebastiano Buti

  45. Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy

    Article • European Journal of Cancer, June 2021, Elsevier

    Dr Sebastiano Buti

  46. Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’

    Article • ESMO Open, June 2021, Elsevier

    Dr Sebastiano Buti

  47. PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors

    Article • Tumori Journal, May 2021, SAGE Publications

    Dr Sebastiano Buti

  48. INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)

    Article • Journal for ImmunoTherapy of Cancer, May 2021, BMJ

    Dr Sebastiano Buti

  49. Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

    Article • European Journal of Cancer, May 2021, Elsevier

    Dr Sebastiano Buti

  50. Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials

    Article • Human Vaccines & Immunotherapeutics, April 2021, Taylor & Francis

    Dr Sebastiano Buti

  51. Cytoreductive nephrectomy in the era of targeted- And immuno- therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature

    Article • Critical Reviews in Oncology/Hematology, April 2021, Elsevier

    Dr Sebastiano Buti

  52. Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?

    Article • European Urology Oncology, April 2021, Elsevier

    Dr Sebastiano Buti

  53. The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer

    Article • ESMO Open, April 2021, Elsevier

    Dr Sebastiano Buti

  54. Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis

    Article • Critical Reviews in Oncology/Hematology, March 2021, Elsevier

    Dr Sebastiano Buti

  55. The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients

    Article • Future Oncology, March 2021, Future Medicine

    Dr Sebastiano Buti

  56. Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO)

    Article • American Journal of Clinical Oncology, January 2021, Wolters Kluwer Health

    Dr Sebastiano Buti

  57. The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the “inflamed tumor” to the “inflamed patient”

    Article • Human Vaccines & Immunotherapeutics, January 2021, Taylor & Francis

    Dr Sebastiano Buti

  58. Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study

    Article • Clinical Medicine Insights Oncology, January 2021, SAGE Publications

    Dr Sebastiano Buti

  59. Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)

    Article • Clinical Medicine Insights Oncology, January 2021, SAGE Publications

    Dr Sebastiano Buti

  60. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

    Article • European Journal of Cancer, January 2021, Elsevier

    Dr Sebastiano Buti

  61. Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?

    Article • Therapeutic Advances in Urology, January 2021, SAGE Publications

    Dr Sebastiano Buti

  62. GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak

    Article • Therapeutic Advances in Urology, January 2021, SAGE Publications

    Dr Sebastiano Buti

  63. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)

    Article • Therapeutic Advances in Medical Oncology, January 2021, SAGE Publications

    Dr Sebastiano Buti

  64. Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis

    Article • Therapeutic Advances in Urology, January 2021, SAGE Publications

    Dr Sebastiano Buti

  65. The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma

    Article • Expert Review of Anticancer Therapy, December 2020, Taylor & Francis

    Dr Sebastiano Buti

  66. Avelumab Maintenance for Urothelial Carcinoma

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, December 2020, New England Journal of Medicine (NEJM/MMS)

    Dr Sebastiano Buti

  67. Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study

    Article • Lung Cancer, December 2020, Elsevier

    Dr Sebastiano Buti

  68. Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study

    Article • Clinical Genitourinary Cancer, December 2020, Elsevier

    Dr Sebastiano Buti

  69. MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma

    Article • Journal of Clinical Pathology, November 2020, BMJ

    Dr Sebastiano Buti

  70. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

    Article • Journal for ImmunoTherapy of Cancer, October 2020, BMJ

    Dr Sebastiano Buti

  71. Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy

    Article • Immunotherapy, October 2020, Future Medicine

    Dr Sebastiano Buti

  72. On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2

    Article • Annals of Oncology, October 2020, Elsevier

    Dr Sebastiano Buti

  73. Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients

    Article • Lung Cancer, October 2020, Elsevier

    Dr Sebastiano Buti

  74. Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis

    Article • Targeted Oncology, August 2020, Springer Science + Business Media

    Dr Sebastiano Buti

  75. Abscopal effect after hypofractionated radiotherapy in metastatic renal cell carcinoma pretreated with pazopanib

    Article • Immunotherapy, August 2020, Future Medicine

    Dr Sebastiano Buti

  76. Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis

    Article • Targeted Oncology, July 2020, Springer Science + Business Media

    Dr Sebastiano Buti

  77. Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions

    Article • Expert Review of Anticancer Therapy, June 2020, Taylor & Francis

    Dr Sebastiano Buti

  78. Predictive Ability for Disease-Free Survival of the GRade, Age, Nodes, and Tumor (GRANT) Score in Patients with Resected Renal Cell Carcinoma

    Article • Current Urology, June 2020, Wolters Kluwer Health

    Dr Sebastiano Buti

  79. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

    Article • Medical Oncology, May 2020, Springer Science + Business Media

    Dr Sebastiano Buti

  80. Activity of lenvatinib plus everolimus combination in a heavily pretreated patient with papillary renal cell carcinoma: a case report

    Article • Tumori Journal, May 2020, SAGE Publications

    Dr Sebastiano Buti

  81. The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors

    Article • Journal of Immunotherapy, May 2020, Wolters Kluwer Health

    Dr Sebastiano Buti

  82. Small renal masses (≤ 4 cm): differentiation of oncocytoma from renal clear cell carcinoma using ratio of lesion to cortex attenuation and aorta–lesion attenuation difference (ALAD) on contrast-enhanced CT

    Article • La radiologia medica, May 2020, Springer Science + Business Media

    Dr Sebastiano Buti

  83. Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis

    Article • Journal of Clinical Medicine, May 2020, MDPI AG

    Dr Sebastiano Buti

  84. Clinicopathologic correlates of pembrolizumab efficacy in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

    Article • April 2020, Cold Spring Harbor Laboratory Press

    Dr Sebastiano Buti

  85. A metanalysis on cabozantinib and bone metastases: true story or commercial gimmick?

    Article • Anti-Cancer Drugs, March 2020, Wolters Kluwer Health

    Dr Sebastiano Buti

  86. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-rela...

    Article • European Journal of Cancer, March 2020, Elsevier

    Dr Sebastiano Buti

  87. Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients

    Article • Scientific Reports, February 2020, Springer Science + Business Media

    Dr Sebastiano Buti

  88. Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study

    Article • Immunotherapy, February 2020, Future Medicine

    Dr Sebastiano Buti

  89. Unlocking the secret of the obesity paradox in renal tumours

    Article • The Lancet Oncology, February 2020, Elsevier

    Dr Sebastiano Buti

  90. Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: a systematic review and meta-analysis

    Article • Revista de Oncología, January 2020, Springer Science + Business Media

    Dr Sebastiano Buti

  91. Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study

    Article • OncoImmunology, January 2020, Taylor & Francis

    Dr Sebastiano Buti

  92. CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors

    Article • Therapeutic Advances in Medical Oncology, January 2020, SAGE Publications

    Dr Sebastiano Buti

  93. Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review

    Article • Therapeutic Advances in Medical Oncology, January 2020, SAGE Publications

    Dr Sebastiano Buti

  94. Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG

    Article • Therapeutic Advances in Medical Oncology, January 2020, SAGE Publications

    Dr Sebastiano Buti

  95. Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study

    Article • Cancer Treatment and Research Communications, January 2020, Elsevier

    Dr Sebastiano Buti

  96. Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors

    Article • Cancers, December 2019, MDPI AG

    Dr Sebastiano Buti

  97. Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies

    Article • Expert Review of Cardiovascular Therapy, December 2019, Taylor & Francis

    Dr Sebastiano Buti

  98. Palliative radiotherapy in advanced cancer patients treated with immune‑checkpoint inhibitors: The PRACTICE study

    Article • Biomedical Reports, December 2019, Spandidos Publications

    Dr Sebastiano Buti

  99. Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review

    Article • Expert Review of Molecular Diagnostics, October 2019, Taylor & Francis

    Sara Elena Rebuzzi, Melissa Bersanelli, Dr Sebastiano Buti

  100. Effectiveness and safety of “real” concurrent stereotactic radiotherapy and immunotherapy in metastatic solid tumors: a systematic review

    Article • Critical Reviews in Oncology/Hematology, October 2019, Elsevier

    Dr Sebastiano Buti

  101. Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature

    Article • Clinical Genitourinary Cancer, October 2019, Elsevier

    Dr Sebastiano Buti

  102. Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients

    Article • Scientific Reports, September 2019, Springer Science + Business Media

    Dr Sebastiano Buti

  103. The way towards tailored treatment for metastatic renal cancer patients in the omics era: are we getting a “transcriptomic compass”?

    Article • Annals of Translational Medicine, September 2019, AME Publishing Company

    Dr Sebastiano Buti

  104. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients

    Article • Seminars in Oncology, August 2019, Elsevier

    Dr Sebastiano Buti

  105. Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population

    Article • Clinical Genitourinary Cancer, August 2019, Elsevier

    Dr Sebastiano Buti

  106. The effect of a treatment delay on outcome in metastatic renal cell carcinoma

    Article • Urologic Oncology Seminars and Original Investigations, August 2019, Elsevier

    Dr Sebastiano Buti

  107. Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab

    Article • Clinical Cancer Research, July 2019, American Association for Cancer Research (AACR)

    Dr Sebastiano Buti

  108. Role of stereotactic body radiation therapy for the management of renal cell carcinoma: tailoring treatment in the era of the “embarrassment of riches”

    Article • Annals of Translational Medicine, July 2019, AME Publishing Company

    Dr Sebastiano Buti

  109. State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough

    Article • Critical Reviews in Oncology/Hematology, July 2019, Elsevier

    Dr Sebastiano Buti

  110. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

    Article • Clinical Lung Cancer, July 2019, Elsevier

    Dr Sebastiano Buti

  111. The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes

    Article • Targeted Oncology, May 2019, Springer Science + Business Media

    Dr Sebastiano Buti

  112. From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC

    Article • Lung Cancer, May 2019, Elsevier

    MD Letizia Gnetti, Dr Sebastiano Buti

  113. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker

    Article • BioMed Research International, April 2019, Hindawi Publishing Corporation

    Dr Sebastiano Buti, francesco pepe

  114. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

    Article • Journal for ImmunoTherapy of Cancer, April 2019, BMJ

    Dr Sebastiano Buti

  115. Pathological nodal staging score for renal cell carcinoma: how to build reliable therapeutic choices basing on assumptions

    Article • Annals of Translational Medicine, March 2019, AME Publishing Company

    Dr Sebastiano Buti

  116. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

    Article • Journal for ImmunoTherapy of Cancer, February 2019, BMJ

    Dr Sebastiano Buti

  117. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

    Article • The Oncologist, February 2019, Oxford University Press (OUP)

    Dr Sebastiano Buti

  118. Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma

    Article • Immunotherapy, January 2019, Future Medicine

    MD Letizia Gnetti, Dr Sebastiano Buti

  119. The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC

    Article • Lung Cancer, January 2019, Elsevier

    Dr Sebastiano Buti

  120. Family history of cancer and DNA damage response genes: Two sides of the same coin?

    Article • Thoracic Cancer, December 2018, Wiley

    Dr Sebastiano Buti

  121. Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis

    Article • Immunotherapy, November 2018, Future Medicine

    Dr Sebastiano Buti

  122. INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study

    Article • Immunotherapy, October 2018, Future Medicine

    Melissa Bersanelli, GAETANO FACCHINI, Dr Sebastiano Buti

  123. Safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma with or without renal failure: the CORE-URO-01 study

    Article • Clinical Genitourinary Cancer, October 2018, Elsevier

    Dr Sebastiano Buti

  124. Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?

    Article • Clinical Genitourinary Cancer, October 2018, Elsevier

    GAETANO FACCHINI, Dr Sebastiano Buti

  125. Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma

    Article • Anticancer Research, October 2018, International Institute of Anticancer Research

    Dr Sebastiano Buti

  126. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2018, New England Journal of Medicine (NEJM/MMS)

    Dr Sebastiano Buti

  127. Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present)

    Article • Future Oncology, September 2018, Future Medicine

    Dr Sebastiano Buti

  128. Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives

    Article • Drug Design Development and Therapy, September 2018, Dove Medical Press

    Dr Sebastiano Buti

  129. Immunotherapy beyond progression in advanced renal cell carcinoma: a case report and review of the literature

    Article • Immunotherapy, September 2018, Future Medicine

    Sara Elena Rebuzzi, Dr Sebastiano Buti

  130. Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date

    Article • Cancer Management and Research, September 2018, Dove Medical Press

    Melissa Bersanelli, Dr Sebastiano Buti

  131. Patient performance status and cancer immunotherapy efficacy: a meta-analysis

    Article • Medical Oncology, August 2018, Springer Science + Business Media

    Melissa Bersanelli, Dr Sebastiano Buti

  132. Radiotherapy for the treatment of distant nodes metastases from oligometastatic urothelial cancer: A retrospective case series

    Article • International Journal of Urology, August 2018, Wiley

    Dr Sebastiano Buti

  133. The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma

    Article • Anti-Cancer Drugs, August 2018, Wolters Kluwer Health

    GAETANO FACCHINI, Dr Sebastiano Buti

  134. Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program

    Article • Clinical Genitourinary Cancer, August 2018, Elsevier

    GAETANO FACCHINI, Dr Sebastiano Buti

  135. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme

    Article • BJU International, July 2018, Wiley

    Giovanni Lo Re, Dr Sebastiano Buti

  136. Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab

    Article • Immunotherapy, July 2018, Future Medicine

    Melissa Bersanelli, MD Letizia Gnetti, Dr Sebastiano Buti

  137. Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population

    Article • Annals of Oncology, July 2018, Elsevier

    Dr Sebastiano Buti

  138. Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study

    Article • Immunotherapy, June 2018, Future Medicine

    Alessio Cortellini, Dr Sebastiano Buti

  139. Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program

    Article • Future Oncology, June 2018, Future Medicine

    Giovanni Lo Re, Dr Sebastiano Buti

  140. Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab

    Article • Immunotherapy, June 2018, Future Medicine

    Dr Sebastiano Buti

  141. Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study

    Article • Drugs in R&D, May 2018, Springer Science + Business Media

    Dr Sebastiano Buti

  142. A new prognostic model for localized renal cell carcinoma

    Article • World Journal of Urology, May 2018, Springer Science + Business Media

    Dr Sebastiano Buti

  143. Durvalumab in Stage III Non–Small-Cell Lung Cancer

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, March 2018, New England Journal of Medicine (NEJM/MMS)

    Dr Sebastiano Buti

  144. The link between calcitriol and anticancer immunotherapy: vitamin D as the possible balance between inflammation and autoimmunity in the immune-checkpoint blockade

    Article • Immunotherapy, November 2017, Future Medicine

    Melissa Bersanelli, Dr Sebastiano Buti

  145. Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study

    Article • Drugs in R&D, September 2017, Springer Science + Business Media

    Dr Sebastiano Buti

  146. Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer

    Article • Urologic Oncology Seminars and Original Investigations, September 2017, Elsevier

    Dr Sebastiano Buti

  147. Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population

    Article • Annals of Oncology, August 2017, Oxford University Press (OUP)

    Dr Sebastiano Buti

  148. Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis

    Article • Oncotarget, August 2017, Impact Journals, LLC

    Dr Sebastiano Buti

  149. Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential

    Article • Therapeutic Advances in Medical Oncology, August 2017, SAGE Publications

    Melissa Bersanelli, Dr Sebastiano Buti

  150. First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study

    Article • Clinical Genitourinary Cancer, August 2017, Elsevier

    GAETANO FACCHINI, Melissa Bersanelli, Dr Sebastiano Buti

  151. Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma

    Article • Therapeutics and Clinical Risk Management, June 2017, Dove Medical Press

    Melissa Bersanelli, Dr Sebastiano Buti

  152. Is Cabozantinib Really Better Than Sunitinib As First-Line Treatment of Metastatic Renal Cell Carcinoma?

    Article • Journal of Clinical Oncology, June 2017, American Society of Clinical Oncology (ASCO)

    Dr Sebastiano Buti

  153. “Finding NEMO” in NRAS -mutant melanoma: a step towards a sequential strategy?

    Article • The Lancet Oncology, June 2017, Elsevier

    Dr Sebastiano Buti

  154. Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?

    Article • PLoS ONE, February 2017, PLOS

    Dr Sebastiano Buti

  155. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs)

    Article • Lung Cancer, February 2017, Elsevier

    Dr Sebastiano Buti, MD Letizia Gnetti

  156. Plasma genotyping for EGFR T790M in non-small cell lung cancer: ready for clinical practice?

    Article • Translational Cancer Research, February 2017, AME Publishing Company

    Dr Sebastiano Buti

  157. From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis

    Article • World Journal of Clinical Oncology, January 2017, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Sebastiano Buti

  158. Pazopanib in Renal Cell Carcinoma Dialysis Patients: A Mini-Review and a Case Report

    Article • Current Drug Targets, October 2016, Bentham Science Publishers

    Dr Sebastiano Buti

  159. Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy

    Article • Core Evidence, September 2016, Dove Medical Press

    Melissa Bersanelli, Dr Sebastiano Buti

  160. The ‘nivolution’ in renal cell carcinoma: behind the scenes of clinical trials

    Article • Future Oncology, September 2016, Future Medicine

    Dr Sebastiano Buti

  161. Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 1 – kidney cancer

    Article • Future Oncology, September 2016, Future Medicine

    Dr Sebastiano Buti, Liang Cheng

  162. Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 – prostate and bladder cancer

    Article • Future Oncology, September 2016, Future Medicine

    Dr Sebastiano Buti, Liang Cheng

  163. Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report

    Article • BMC Cancer, August 2016, Springer Science + Business Media

    Dr Sebastiano Buti

  164. Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review

    Article • Clinical Genitourinary Cancer, August 2016, Elsevier

    Dr Sebastiano Buti

  165. Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma

    Article • Oncotarget, March 2016, Impact Journals, LLC

    Dr Sebastiano Buti

  166. Non-clear-cell renal carcinoma therapy: handle with care

    Article • The Lancet Oncology, March 2016, Elsevier

    Dr Sebastiano Buti

  167. Drug-Induced Megaloblastic Anemia

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, February 2016, New England Journal of Medicine (NEJM/MMS)

    Dr Sebastiano Buti

  168. AR-V7 and prostate cancer: The watershed for treatment selection?

    Article • Cancer Treatment Reviews, February 2016, Elsevier

    Dr Sebastiano Buti

  169. Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review

    Article • Gynecologic and Obstetric Investigation, January 2016, Karger Publishers

    Dr Sebastiano Buti

  170. Combination therapy in kidney cancer: the next revolution?

    Article • The Lancet Oncology, November 2015, Elsevier

    Dr Sebastiano Buti

  171. Osteoblastic Progression during EGFR Tyrosine Kinase Inhibitor Therapy in Mutated Non-small Cell Lung Cancer: A Potential Blunder

    Article • Tumori Journal, September 2015, SAGE Publications

    Dr Sebastiano Buti

  172. ALKandROS1rearrangements tested by fluorescencein situhybridization in cytological smears from advanced non-small cell lung cancer patients

    Article • Diagnostic Cytopathology, July 2015, Wiley

    Dr Sebastiano Buti

  173. Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients

    Article • Lung Cancer, June 2015, Elsevier

    Dr Sebastiano Buti

  174. Corrigendum

    Article • Future Oncology, June 2015, Future Medicine

    Dr Sebastiano Buti, GAETANO FACCHINI, Giovanni Lo Re

  175. Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients

    Article • Future Oncology, March 2015, Future Medicine

    GAETANO FACCHINI, Dr Sebastiano Buti, Giovanni Lo Re

  176. Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy

    Article • Targeted Oncology, January 2015, Springer Science + Business Media

    Dr Sebastiano Buti

  177. Very late recurrence of an apparently benign pheochromocytoma

    Article • Journal of Cancer Research and Therapeutics, January 2015, Medknow

    Dr Sebastiano Buti, MD Letizia Gnetti

  178. Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH

    Article • Tumori Journal, January 2015, Wichtig

    Dr Sebastiano Buti

  179. Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?

    Article • Future Oncology, January 2015, Future Medicine

    Dr Sebastiano Buti

  180. Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma

    Article • The Journal of Urology, January 2015, Elsevier

    Dr Sebastiano Buti

  181. Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors

    Article • Annals of Surgical Oncology, December 2014, Springer Science + Business Media

    Dr Sebastiano Buti

  182. Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon-α (IFN-α) in Operable Renal Cell Carcinoma (RCC)

    Article • Journal of Immunotherapy, November 2014, Wolters Kluwer Health

    Dr Sebastiano Buti

  183. Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan

    Article • Lung Cancer, October 2014, Elsevier

    Dr Sebastiano Buti

  184. Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy

    Article • Cancers, September 2014, MDPI AG

    Dr Sebastiano Buti

  185. Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg)

    Article • Targeted Oncology, September 2014, Springer Science + Business Media

    Dr Sebastiano Buti, Giovanni Lo Re

  186. BOLERO-3 results: pharmacological activity or pharmacokinetic effect?

    Article • The Lancet Oncology, July 2014, Elsevier

    Dr Sebastiano Buti

  187. Axitinib dose titration: what's the limiting factor?

    Article • The Lancet Oncology, November 2013, Elsevier

    Dr Sebastiano Buti

  188. Colony-Stimulating Factors for Febrile Neutropenia

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, July 2013, New England Journal of Medicine (NEJM/MMS)

    Dr Sebastiano Buti

  189. Does the Cetuximab Plus Paclitaxel Combination Deserve to Be Studied in a Phase III Trial?

    Article • Journal of Clinical Oncology, April 2013, American Society of Clinical Oncology (ASCO)

    Dr Sebastiano Buti

  190. Chemotherapy in metastatic renal cell carcinoma today? A systematic review

    Article • Anti-Cancer Drugs, April 2013, Wolters Kluwer Health

    Dr Sebastiano Buti

  191. When a thymic carcinoma “becomes” a GIST

    Article • Lung Cancer, April 2013, Elsevier

    Dr Sebastiano Buti

  192. Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial

    Article • Journal of Clinical Oncology, December 2012, American Society of Clinical Oncology (ASCO)

    Dr Sebastiano Buti

  193. Systemic adjuvant therapies in renal cell carcinoma

    Article • Oncology Reviews, October 2012, PAGEPress Publications

    Dr Sebastiano Buti

  194. Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey

    Article • BJU International, February 2012, Wiley

    Dr Sebastiano Buti

  195. Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors

    Article • Annals of Oncology, February 2012, Oxford University Press (OUP)

    Dr Sebastiano Buti

  196. Changes in Lymphocyte Count Induced by Repeated Cycles with Low-Dose Interleukin-2 and Interferon-α in 146 Patients with Renal Cell Carcinoma

    Article • Tumori Journal, January 2012, SAGE Publications

    Dr Sebastiano Buti

  197. Impressive Response With Imatinib in a Heavily Pretreated Patient With Metastatic c-KIT Mutated Thymic Carcinoma

    Article • Journal of Clinical Oncology, November 2011, American Society of Clinical Oncology (ASCO)

    Dr Sebastiano Buti

  198. Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)

    Article • Lung Cancer, July 2011, Elsevier

    Dr Sebastiano Buti

  199. Renal Cell Cancer: State of the Art in Adjuvant Therapy

    Article • Recent Patents on Anti-Cancer Drug Discovery, November 2010, Bentham Science Publishers

    Dr Sebastiano Buti

  200. Dose-finding Trial of a Combined Regsimen With Bevacizumab, Immunotherapy, and Chemotherapy in Patients With Metastatic Renal Cell Cancer: An Italian Oncology Group for Clinical Research (GOIRC) Study

    Article • Journal of Immunotherapy, September 2010, Wolters Kluwer Health

    Dr Sebastiano Buti, Giovanni Lo Re

  201. Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial

    Article • Cancer Chemotherapy and Pharmacology, March 2010, Springer Science + Business Media

    Dr Sebastiano Buti

  202. Dose-dense Chemotherapy in Metastatic Gastric Cancer with a Modified Docetaxel-Cisplatin-5-Fluorouracil Regimen

    Article • Tumori Journal, January 2010, SAGE Publications

    Dr Sebastiano Buti

  203. Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-α for metastatic renal cell cancer

    Article • Medical Oncology, September 2009, Springer Science + Business Media

    Dr Sebastiano Buti

  204. Chronically Administered Immunotherapy with Low-Dose IL-2 and IFN-α in Metastatic Renal Cell Carcinoma: A Feasible Option for Patients with a Good Prognostic Profile

    Article • Oncology, December 2008, Karger Publishers

    Dr Sebastiano Buti

  205. Role of Chemotherapy With Gemcitabine Plus 5-fluorouracil and Chemoimmunotherapy in Metastatic Renal Cell Cancer (mRCC)

    Article • Journal of Immunotherapy, October 2007, Wolters Kluwer Health

    Dr Sebastiano Buti

  206. A Pilot Phase ii Study of Chemotherapy with Oxaliplatin, Folinic acid, 5-Fluorouracil and Irinotecan in Metastatic Gastric Cancer

    Article • Tumori Journal, April 2007, SAGE Publications

    Dr Sebastiano Buti

  207. Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: a case report

    Article • Anti-Cancer Drugs, March 2007, Wolters Kluwer Health

    Dr Sebastiano Buti

  208. Immunotherapy options in metastatic renal cell cancer: where we are and where we are going

    Article • Expert Review of Anticancer Therapy, October 2006, Taylor & Francis

    Dr Sebastiano Buti